Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | HRH1 | P35367 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | HTR3A | P46098 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | GHSR | Q92847 | 1/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caroverine SCHEMBL28086487 | 0.88 | DRD3 (0.89) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL31128388 | 0.87 | DRD3 (1.00) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL25946 | 0.87 | DRD3 (1.00) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL2258789 | 0.86 | DRD3 (0.98) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL1649725 | 0.85 | DRD3 (0.96) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| SCHEMBL3888449 | 0.85 | MLNR (0.57) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL7279211 | 0.82 | DRD3 (0.85) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| SCHEMBL3910855 | 0.78 | MAOA (0.52) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| Caroverine SCHEMBL11330670 | 0.78 | DRD3 (0.76) | MLNRADORA3ADRA2BADRA2CHTR2A | |
| SCHEMBL3903902 | 0.76 | PDE4D (0.46) | MLNRADORA3ADRA2BADRA2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530455-B1 | A PHARMACEUTICAL FORMULATION AND ITS USE IN THE TREATMENT OF INNER EAR DISEASES | PHAFAG AG (LI) | 2009-03-18 | — | — | EP | claimed |
| EP-1087768-B1 | USE OF 1-(AMINOALKYL)-3-QUINOXALINE-2-ONE DERIVATIVES FOR THE PREPARATION OF COMPOUNDS HAVING AN ANTIOXIDANT ACTION | PHAFAG AG (LI) | 2009-01-14 | — | — | EP | claimed |
| US-20080200424-A1 | Preparation for Treating Cancer | IMMUNOPHARM AG (LI) | 2008-08-21 | — | — | US | claimed |
| EP-1742636-A2 | PREPARATION FOR THE TREATMENT CANCER | Immunopharm Aktiengesellschaft (LI) | 2007-01-17 | — | — | EP | claimed |
| US-20050288292-A1 | Pharmaceutical formulation and its use in the treatment of inner ear diseases | PHAFAG AG (LI) | 2005-12-29 | — | — | US | claimed |
| WO-2005105098-A2 | PREPARATION FOR THE TREATMENT OF CANCER | IMMUNOPHARM AKTIENGESELLSCHAFT (LI) | 2005-11-10 | — | — | WO | claimed |
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | PHAFAG AKTIENGESELLSCHAFT (LI) | 2001-07-05 | — | — | US | claimed |
| EP-0542689-B1 | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions | PHAFAG AG (LI) | 1998-09-23 | — | — | EP | claimed |
| US-5563140-A | Use of 1-(aminoalkyl)-3-(benzyl)-quinoxaline-2-one derivatives for the preparation of neuroprotective compositions | PHAFAG AKTIENGESELLSCHAFT (LI) | 1996-10-08 | — | — | US | claimed |
| EP-0542689-A1 | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions | PHAFAG AKTIENGESELLSCHAFT (LI) | 1993-05-19 | — | — | EP | claimed |
| EP-1530455-B1 | A PHARMACEUTICAL FORMULATION AND ITS USE IN THE TREATMENT OF INNER EAR DISEASES | PHAFAG AG (LI) | 2009-03-18 | — | — | EP | disclosed |
| EP-1087768-B1 | USE OF 1-(AMINOALKYL)-3-QUINOXALINE-2-ONE DERIVATIVES FOR THE PREPARATION OF COMPOUNDS HAVING AN ANTIOXIDANT ACTION | PHAFAG AG (LI) | 2009-01-14 | — | — | EP | disclosed |
| US-20080200424-A1 | Preparation for Treating Cancer | IMMUNOPHARM AG (LI) | 2008-08-21 | — | — | US | disclosed |
| US-20050288292-A1 | Pharmaceutical formulation and its use in the treatment of inner ear diseases | PHAFAG AG (LI) | 2005-12-29 | — | — | US | disclosed |
| US-6573265-B2 | Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents; | PHAFAG AKTIENGESELLSCHAFT (LI) | 2003-06-03 | — | — | US | disclosed |
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | PHAFAG AKTIENGESELLSCHAFT (LI) | 2001-07-05 | — | — | US | disclosed |
| EP-1087768-A1 | USE OF 1-(AMINOALKYL)-3-QUINOXALINE-2-ONE DERIVATIVES FOR THE PREPARATION OF COMPOUNDS HAVING AN ANTIOXIDANT ACTION | PHAFAG AKTIENGESELLSCHAFT (LI) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999066931-A1 | USE OF 1-(AMINOALKYL)-3-QUINOXALINE-2-ONE DERIVATIVES FOR THE PREPARATION OF COMPOUNDS HAVING AN ANTIOXIDANT ACTION | PHAFAG AKTIENGESELLSCHAFT (LI) | 1999-12-29 | — | — | WO | disclosed |
| EP-0542689-B1 | Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions | PHAFAG AG (LI) | 1998-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | GLS, GLUL, GLS2 | MLNR 1977/4885ADORA3 705/4885ADRA2B 1330/4885 |
| US-20050288292-A1 | Pharmaceutical formulation and its use in the treatment of inner ear diseases | SLC26A4, TIMM10, AQP1 | MLNR 3939/4885ADORA3 1004/4885ADRA2B 1164/4885 |
| US-20080200424-A1 | Preparation for Treating Cancer | CBS, SCLY, GPX1 | MLNR 3042/4885ADORA3 3222/4885ADRA2B 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.